Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
If a patient is diagnosed with either high-risk prostate cancer that appears to be confined to the prostate or potentially locally advanced disease that may have progressed into nearby pelvic tissues, the question arises whether it is better to simply radiate the prostate alone with curative intent or to radiate both the prostate and the [...]
Filed under: Management, Treatment | Tagged: PORT, prostate only radiotherapy, whole pelvis radiotherapy, WPRT | 1 Comment »
A recent study has assessed the risk of bleeding as a consequence of radiation therapy for localized prostate cancer in men being treated with anticoagulants .
Filed under: Management, Treatment | Tagged: anticoagulant, bleeding, clopidogrel, EBRT, external beam radiation, risk, warfarin | Leave a Comment »
It is still not unusual, in large parts of the world, for patients to be diagnosed with prostate cancer and treated with hormone therapy as a first-line treatment or following a period of active surveillance or monitoring — for all sorts of reasons.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: localized, palliation, radiotherapy, symptoms | Leave a Comment »
Some years have passed since D’Amico and colleagues developed their risk classification system for newly diagnosed prostate cancer patients which placed any patient with a PSA > 20 ng/ml into the high-risk category. And since the introduction of that classification system, we are aware of limited data on the long-term outcomes of surgical treatment of [...]
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: "high risk", patients, surgery | Leave a Comment »
As mentioned on Tuesday this week, an article and an editorial on prostate cancer screening were just published in CA: A Cancer Journal for Clinicians. Initial media reports on the article and editorial implied that the authors were suggesting that there is no value to testing for prostate cancer. Let us be very clear. This [...]
Filed under: Diagnosis, Prevention, Risk | Tagged: Prevention, risk, screening, testing | 8 Comments »
Today’s news reports discuss such issues as: Sextant biopsy in diagnosis of unilateral prostate cancer Aggressiveness of prostate cancer in man diagnosed with PSA < 4 ng/ml The potential of 3T MRI in prostate cancer prognosis pre-surgery Surgical margins and risk for biochemical recurrence post-surgery
Filed under: Uncategorized | Tagged: 3T MRI, aggressiveness, biopsy, low PSA levels, prognosis, risk, sextant, surgical margins | Leave a Comment »
This initial report contains inaccuracies and is based solely on the abstract of the original paper. A more detailed and accurate assessment of this paper was developed on July 4 after assessment of the complete published paper. Readers are advised to read newer report but you can
Filed under: Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound | 2 Comments »
A new — but very small and short-term study — has attempted to assess the baseline prevalence of cognitive impairment in older men treated with androgen deprivation therapy (ADT) and changes in cognitive performance over time.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, cognitive, function, hormone, performance, therapy | 1 Comment »
In today’s news reports we cover items on: Prediction of risk for prostate cancer under-grading based on biopsy data The obesity/risk equation in prostate cancer Capecitabine + docetaxel in metastatic CRPC
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: biopsy, capecitabine, CRPC, docetaxel, Gleason score, obesity, risk, under-grading | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site